OncoDxRx has taken a significant step toward enhancing its drug efficacy/response prediction capabilities by successfully testing the deployment of its PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) technology on real-world cancer patients, the results will be published in the prestigious journal Global Translational Medicine in March.

This milestone, achieved in collaboration with Shin-Kong hospital in Taiwan, demonstrates a leap in operational flexibility and clinical validity, allowing the sophisticated PGA technology to extend its diagnostic reach from US to overseas. The test hailed as a success, underscores a broader push by OncoDxRx to adapt and integrate advanced technologies in response to escalating global cancer threats, and particularly to support those patients unresponsive to precision medicine.

The PGA platform has been a cornerstone of OncoDxRx’s exclusive precision diagnostics pipelines, designed to identify the best performing drugs for individual patients from a library of 700+ existing cancer drugs including approved, in clinical trials, and investigational.

Its deployment on real-world patients marks a significant milestone of this technology. OncoDxRx emphasized the test’s importance in optimizing the system’s clinical utility, validity and interoperability, noting that it represents “one more step toward an ever more clinically proven and interoperable gene-to-drug mapping capability.”

This cross-lab validation and integration could enable OncoDxRx to rapidly deploy PGA drug response predictive power around the world, improving patient outcomes in dynamic scenarios. The successful PGA test suggests OncoDxRx is now exploring ways to project drug response prediction capability further, potentially to counter cancer threats more flexibly across country boundaries.

The low patient response rates and frequent drug resistance events have exposed vulnerabilities in precision medicine, prompting OncoDxRx to prioritize innovation in drug response prediction technology. “This is about staying ahead in a game that’s speeding up,” said OncoDxRx. “PGA gives patients more treatment options without being tied to the exhaustion of standard of care.”

The industry might draw inspiration, though PGA stands out as the world-first and only “all-in” drug response prediction technology, a point of pride emphasized by OncoDxRx. “There is no equivalent or anything like it what so ever.”

As the clinicians navigate a world of faster and deadlier anti-cancer weapons, OncoDxRx’s PGA breakthrough offers a glimpse of the future: accurate, accessible, affordable and ready to pivot.